No Reduced CVD Risk for SBP <120 mm Hg in Type 2 Diabetes
WEDNESDAY, April 11, 2018 -- For patients with type 2 diabetes mellitus (T2DM), there is no reduction in cardiovascular disease (CVD) risk with achieved systolic blood pressure (SBP) of <120 mm Hg versus <130 or <140 mm Hg, according to a study published online March 28 in Diabetes Care.
Eric Yuk Fai Wan, from the University of Hong Kong, and colleagues conducted a retrospective cohort study of 28,014 primary care adult patients with T2DM with no prior CVD diagnosis. The authors identified a total of 2,079, 10,851, and 15,084 matched patients with achieved SBP measurements of <120, <130, and <140 mm Hg, respectively.
The researchers found that the incidence of CVD was 15.3, 9.1, and 10.8 percent in patients who achieved SBP measures of <120, <130, and <140 mm Hg, respectively, over a median follow-up of 4.8 years (incidence rates, 34.3, 20.4, and 21.4 per 1,000 person-years, respectively). Compared with achieved SBP <130 mm Hg and achieved SBP of <140 mm Hg, achieved SBP <120 mm Hg was correlated with an increased risk of CVD (hazard ratios, 1.75 and 1.67, respectively). A significant reduction in CVD risk was seen for patients aged <65 years with achieved SBP <130 versus <140 mm Hg (hazard ratio, 0.81).
"Our findings support a SBP treatment target of 140 mm Hg and suspect no risk reduction attenuation on CVD for lower SBP targets," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: April 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.